We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 1

Figure 1. From: EXCESS MORTALITY IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C TREATED WITH LONG-TERM PEGINTERFERON.

Overview of the HALT-C Trial, showing flow of the patient cohort from time of randomization, through the 3.5 years of the randomized trial phase, and during the extended follow-up phase showing numbers of deaths.

Adrian M. Di Bisceglie, et al. Hepatology. ;53(4):1100-1108.
2.
Figure 2

Figure 2. From: EXCESS MORTALITY IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C TREATED WITH LONG-TERM PEGINTERFERON.

Cumulative rates of death by fibrosis/cirrhosis stratum in the HALT-C Trial cohort: Kaplan-Meier analysis of 622 patients in the fibrosis stratum (Fibrosis: dotted line) versus 428 patients in the cirrhosis stratum (Cirrhosis: solid line). The vertical line at 3.5 years marks the end of the randomized trial phase.

Adrian M. Di Bisceglie, et al. Hepatology. ;53(4):1100-1108.
3.
Figure 3

Figure 3. From: EXCESS MORTALITY IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C TREATED WITH LONG-TERM PEGINTERFERON.

Cumulative rates of death by randomization group in the HALT-C Trial cohort: Kaplan-Meier analysis of deaths in 517 patients randomized to the treatment group (Trt: dotted line) versus 533 patients randomized to the controls group (Cntl: solid line). The vertical line at 3.5 years marks the end of the randomized trial phase

Adrian M. Di Bisceglie, et al. Hepatology. ;53(4):1100-1108.
4.

Figure 4. From: EXCESS MORTALITY IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C TREATED WITH LONG-TERM PEGINTERFERON.

Cumulative rates of death by fibrosis/cirrhosis stratum and randomization group in the HALT-C Trial cohort: All deaths (A), Liver-related deaths only (B), and Non-liver-related deaths only (C). Kaplan-Meier analysis of deaths in 309 patients in the fibrosis stratum and treatment group (Fib Trt), 313 patients in the fibrosis stratum and control group (Fib Cntl),208 patients in the cirrhosis stratum and treatment group (Cirr Trt), and220 patients in the cirrhosis stratum and control group (Cirr Cntl). The vertical line at 3.5 years marks the end of the randomized trial phase.

Adrian M. Di Bisceglie, et al. Hepatology. ;53(4):1100-1108.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk